- Home
- FRPH vs EYPT Comparison
FRPH vs EYPT Comparison
Compare FRPH & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRPH | EYPT |
|---|---|---|
| Founded | 1986 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.6M | 312.1M |
| IPO Year | 1995 | 2005 |
Fundamental Metrics
Financial Performance| Metric | FRPH | EYPT |
|---|---|---|
| Price | $20.49 | $3.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $25.91 |
| AVG Volume (30 Days) | 87.6K | ★ 3.1M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $42,846,000.00 | $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $943.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.57 | N/A |
| 52 Week Low | $20.53 | $3.27 |
| 52 Week High | $25.74 | $19.11 |
Technical Indicators
Market Signals| Indicator | FRPH | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 31.00 | 29.43 |
| Support Level | N/A | N/A |
| Resistance Level | $23.10 | $14.72 |
| Average True Range (ATR) | 0.39 | 0.29 |
| MACD | -0.04 | 0.18 |
| Stochastic Oscillator | 0.00 | 2.27 |
Price Performance
Historical ComparisonAbout FRPH FRP Holdings Inc.
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, industrial, and office (the Development Segment), and (iv) management of mixed-use residential/retail properties owned through joint ventures.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.